Stocktoria
MiniMed Group, Inc. MMED
MiniMed Group, Inc. (MMED) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $3.1B at a -10.7% net margin.
Beneish M-score: -3.16 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-04 | Wells Fargo | Overweight (main) |
| 2026-05-18 | B of A Securities | Buy (main) |
| 2026-05-12 | Benchmark | Buy (init) |
| 2026-04-01 | Barclays | Overweight (init) |
| 2026-03-31 | William Blair | Outperform (init) |
| 2026-03-31 | Citigroup | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.14 |
| Retained earnings / assets | -0.025 |
| EBIT / assets | -0.041 |
| Equity / liabilities | 3.544 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
| TFX | TELEFLEX INC | 5/9 | 3.56 | — | +17.2% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
About MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
FAQ
Is MMED financially healthy?
MiniMed Group, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MMED pay a dividend?
No, MiniMed Group, Inc. does not currently pay a dividend.
How profitable is MMED?
In FY2026, MiniMed Group, Inc. had a net margin of -10.7% and a return on equity of -9.2%.
What is the analyst price target for MMED?
The average Wall-Street price target for MiniMed Group, Inc. is $20.91, from 11 analysts (consensus: strong buy).
Is MMED a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MiniMed Group, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-04-24. Facts plus Stocktoria's own computed scores — not investment advice.